What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The ALLEGRO 2b/3 trial demonstrated that ritlecitinib significantly improved hair regrowth compared to placebo, with a response rate of 23.0% at 24 weeks and 43.2% at 48 weeks. This indicates a clear clinical advantage over standard care, although the evidence is primarily from Phase 2/3 trials.
Does the economic case hold at the expected price? — Cost effectiveness
The most likely ICER for ritlecitinib was determined to be £25,406 per QALY gained, which is within the acceptable range for Healthcare resources. The committee noted that the innovative nature of the treatment and potential uncaptured benefits justified this cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
Patient experts reported significant psychosocial impacts of severe alopecia areata, and the committee acknowledged that hair regrowth could lead to substantial improvements in quality of life. However, the evidence for HRQoL improvements was not robustly quantified across all domains.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ritlecitinib exhibited a very good safety profile, with serious adverse events being similar to placebo. Most adverse events reported were mild to moderate, indicating good tolerability.
Was the drug compared against what payers expect? — Comparator Selection
The clinical trials compared ritlecitinib against placebo, which is appropriate given the lack of licensed treatments for severe alopecia areata. However, the absence of head-to-head comparisons with existing treatments limits the robustness of the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The ALLEGRO trials included a representative sample of patients aged 12 and over, although the proportion of young people was slightly underrepresented compared to clinical practice. Overall, the population was deemed generalizable.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ritlecitinib can be integrated into existing care pathways with minor adjustments, as it does not require new infrastructure or extensive training for healthcare providers.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of ritlecitinib is manageable, especially considering the commercial arrangement that provides a discount. The treatment is expected to be resource-efficient given its cost-effectiveness.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by the ALLEGRO 2b/3 and ALLEGRO-LT trials, which are well-designed and provide robust data, although there are some limitations regarding long-term follow-up.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding long-term effects and the generalizability of some data, the committee noted that the treatment addresses a significant unmet need, which mitigates some of the concerns.
